CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
eribulin mesylatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01613768
NCT01613768Phase 2Completed
CompareCT.gov

Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers

University of Washington·interventional·Posted Jun 7, 2012·Updated Sep 28, 2018

In Brief

A Phase 2 clinical trial evaluating eribulin mesylate for Recurrent Salivary Gland Cancer and 3 related conditions. Completed, enrolled 29 participants across 1 site.

Detailed Summary

Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer, Stage IVB Salivary Gland Cancer, Stage IVC Salivary Gland Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2012
Enrollment StartMay 8, 2012
Primary CompletionAug 23, 2017
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 14.1 years ago

Interventions

eribulin mesylatedrug

Given IV